II. Indications
-
HIV Infection (part of combination therapy)
- Multiresistant HIV in treatment experienced patients
III. Mechanism
- Ibalizumab is a recombinant Monoclonal Antibody inhibiting HIV-1 from infecting CD4+ T Cells
- Post-Attachment Inhibitor
- Binds domain 2 of CD4, inhibiting post-attachment steps needed for HIV entry into host cells
- Blocks cell-cell fusion mediated HIV Transmission
IV. Dosing: Adult
-
General
- Indicated only in multiresistant HIV in treatment experienced patients
- Administer in combination with other Antiretrovirals
- Inject immediately after reconstituting solution
- Arm cephalic veins are preferred IV infusion sites
- Load: 2000 mg IV over 30 minutes (and monitor for 1 hour)
- Maintenance: 800 mg IV over 30 minutes every 14 days
- Monitor for 15 minutes (monitor up to 60 minutes if prior reaction)
- Give loading dose instead, if maintenance dose is delayed >3 days (>17 days from last dose)
V. Adverse Effects
VI. Safety
- Pregnancy
- Unknown safety in pregnancy (registry exists)
- Increased fetal exposure after 20 weeks